immunotherapeutics – Talk Bio

Actionable Insights Powered by AI

MoonLake revives FDA push; biotech trio to debut in Hong Kong

2 weeks ago talkbio0Tagged * * Investor Day, Asia, Biological Factors, Blackfoot language, Capital, Hidradenitis Suppurativa, Hong Kong, HS drug approval pathway, immunotherapeutics, License Application, Market, MIRA trial, MoonLake, sonelokimab, Type B meeting, United States Food and Drug Administration, VELA-1 trial, VELA-2 trial

MoonLake Immunotherapeutics; Sonelokimab; Hidradenitis Suppurativa; FDA Type B meeting; Biologics License Application; BLA H2 2026; VELA-1 trial; VELA-2 trial; MIRA trial; HS drug approval pathway; investor day February 23 2026; Hong Kong biotech IPOs; Hong Kong listing; Asia biotech capital markets

HOOKIPA Pharma Terminates Acquisition Talks with Poolbeg Pharma

11 months ago talkbio0Tagged acquisition termination, biotech merger, HOOKIPA, immunotherapeutics, Pharma, Poolbeg

biotech merger, acquisition termination, HOOKIPA Pharma, Poolbeg Pharma, immunotherapeutics, rare disease